{"product_id":"lly-bcg-matrix","title":"(LLY) Eli Lilly and Company BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Eli Lilly and Company BCG Matrix helps you understand how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. This page already shows a real preview of the report content, so you can see the format and quality before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMounjaro, \u0026gt;$11B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMounjaro generated about $11.5 billion in 2024 sales, making it Eli Lilly and Company’s top diabetes growth engine. It has a leading position in the incretin class, which kept expanding fast in 2024 and 2025. That mix of strong sales, share gains, and rapid category growth fits a classic Star in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZepbound, \u0026gt;$4B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZepbound crossed $4 billion in 2024 sales, showing how fast Eli Lilly and Company built its obesity franchise after launch. Demand kept rising in 2025 as U.S. obesity prevalence stayed near 42% of adults and global access broadened, so the market is still expanding. With high growth and strong share, Zepbound fits the Star quadrant in Eli Lilly and Company’s BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerzenio, \u0026gt;$5B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerzenio is Eli Lilly and Company’s key oncology star, with 2024 sales of about $5.3 billion, up 33% year over year. It treats HR+, HER2- breast cancer in both metastatic and early settings, which keeps demand broad and durable. That growth has kept Verzenio in a leading market position and made it Lilly’s main cancer growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTaltz, nearly $3B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTaltz fits Star status in Eli Lilly and Company BCG Matrix: 2024 sales were nearly $3B, powered by psoriasis and psoriatic arthritis use. The immunology market is still growing, so strong brand demand and broad indications support high share in a large, expanding category.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTaltz: nearly $3B 2024 sales\u003c\/li\u003e\n\u003cli\u003eMultiple immunology indications\u003c\/li\u003e\n\u003cli\u003ePsoriasis and psoriatic arthritis\u003c\/li\u003e\n\u003cli\u003eLarge, expanding specialty market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eJardiance, blockbuster cardio-renal franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJardiance is a Star-like asset for Eli Lilly and Company: it posted about $8.6 billion in 2024 global sales, driven by type 2 diabetes, heart failure, and CKD use. Lilly and Boehringer Ingelheim still benefit from strong scale, broad label reach, and durable demand, so the franchise keeps showing market leadership and steady growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003e2024 sales: about $8.6 billion.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eMulti-use demand: diabetes, HF, CKD.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAlliance-backed scale supports leadership.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLilly’s Star Brands Are Powering Growth Across Key Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMounjaro, Zepbound, Verzenio, Taltz, and Jardiance all fit Stars in Eli Lilly and Company’s BCG Matrix because each combines strong share with a fast-growing market. Mounjaro led with about $11.5 billion in 2024 sales, Zepbound topped $4 billion, Verzenio reached about $5.3 billion, Taltz was nearly $3 billion, and Jardiance was about $8.6 billion. Their 2025 demand stayed firm across diabetes, obesity, oncology, immunology, and cardio-renal care.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eStar Driver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMounjaro\u003c\/td\u003e\n\u003ctd\u003e$11.5B\u003c\/td\u003e\n\u003ctd\u003eIncretin share gain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound\u003c\/td\u003e\n\u003ctd\u003e$4B+\u003c\/td\u003e\n\u003ctd\u003eObesity growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVerzenio\u003c\/td\u003e\n\u003ctd\u003e$5.3B\u003c\/td\u003e\n\u003ctd\u003eOncology leadership\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTaltz\u003c\/td\u003e\n\u003ctd\u003e~$3B\u003c\/td\u003e\n\u003ctd\u003eImmunology demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJardiance\u003c\/td\u003e\n\u003ctd\u003e$8.6B\u003c\/td\u003e\n\u003ctd\u003eMulti-use scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eEli Lilly BCG Matrix: clear quadrant view of drugs to invest in, hold, or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eEli Lilly BCG Matrix: one-page view of each business unit for quick, clear strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eEli Lilly and Company Reference Sources provide a credible audit trail that supports faster, more confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrulicity, \u0026gt;$5B 2024 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrulicity brought in $5.25B in 2024 sales, down from $5.56B in 2023, so it is still a major revenue engine for Eli Lilly and Company. With GLP-1 rivals like Novo Nordisk's Ozempic and Eli Lilly and Company's own Mounjaro taking share, growth has slowed and stayed negative. That mature, high-cash, low-growth profile fits a Cash Cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHumalog family, legacy rapid insulin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHumalog, launched in 1996, is Lilly's legacy rapid insulin with deep prescriber familiarity and long market use. Growth is now low, but it still adds steady cash as diabetes demand stays large. In 2024, Lilly posted $45.0 billion in revenue, and Humalog remains a mature cash engine inside that base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHumulin line, long-established human insulin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHumulin is a classic mature diabetes line: low growth, stable demand, and steady cash generation with little extra capital. In Eli Lilly and Company’s 2024 base, total revenue was $45.0 billion, and legacy insulin products like Humulin help fund newer growth drugs while the market stays structurally flat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBasaglar, mature insulin glargine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBasaglar is Lilly’s insulin glargine U-100 biosimilar in a mature basal-insulin market. Demand is steady, but growth is capped by heavy competition from long-acting insulins and biosimilars. That makes it a classic Cash Cow: low growth, reliable cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable volume\u003c\/li\u003e\n\u003cli\u003eLow category growth\u003c\/li\u003e\n\u003cli\u003eStrong cash generation\u003c\/li\u003e\n\u003cli\u003ePrice pressure risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn 2025, the global insulin glargine market remained dominated by cost-focused switching, so Basaglar can still throw off cash even without fast expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEmgality, migraine brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmgality is a mature migraine and cluster headache brand, approved in 2018 for migraine prevention and in 2019 for episodic cluster headache. With an established patient base and no launch-phase spend, its growth is steadier and fits Eli Lilly and Company’s Cash Cow bucket more than a Star.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature brand, not early-stage\u003c\/li\u003e\n\u003cli\u003eBroad U.S. migraine base\u003c\/li\u003e\n\u003cli\u003eLower growth, steadier cash flow\u003c\/li\u003e\n\u003cli\u003eSupports profit, not breakout growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEli Lilly’s Cash Cows Keep the Cash Flowing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company’s Cash Cows are mature brands with steady demand and limited growth, led by Trulicity, Humalog, Humulin, Basaglar, and Emgality. Trulicity still posted $5.25B in 2024 sales, while Eli Lilly and Company totaled $45.0B in revenue, so these lines still fund newer launches. Their value comes from cash, not expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrulicity\u003c\/td\u003e\n\u003ctd\u003e$5.25B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHumalog\u003c\/td\u003e\n\u003ctd\u003eMature insulin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHumulin\u003c\/td\u003e\n\u003ctd\u003eStable demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBasaglar\u003c\/td\u003e\n\u003ctd\u003ePrice pressured\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmgality\u003c\/td\u003e\n\u003ctd\u003eSteady cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eEli Lilly and Company Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Eli Lilly and Company BCG Matrix preview you see here is the exact same document you’ll receive after purchase. There are no hidden pages, demo sections, or watermarks—just the complete, polished report. It’s ready to download, use, and share right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCymbalta, generic since 2014\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCymbalta is an older SNRI that lost U.S. exclusivity in 2013, and generics have dominated since 2014. Eli Lilly and Company’s branded share is now minimal, with sales pressure coming from low-cost copies in a mature antidepressant and pain market. That mix of low growth and low share fits the Dogs bucket in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZyprexa, generic since 2011\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZyprexa has been generic since 2011, so Eli Lilly and Company now treats it as a legacy brand, not a growth engine. In a mature antipsychotic market, sales growth is minimal and pricing pressure is high. That profile fits a Dog in the BCG Matrix: low growth, weak strategic priority, and limited cash-generation upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlimta, patent expiry era asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlimta (pemetrexed) is a clear Dog for Eli Lilly and Company: U.S. patent protection ended, and generic rivals have cut pricing and share for years. Demand in NSCLC and mesothelioma is mature, so growth is weak and the product no longer supports high-margin economics. In 2025\/2026, Alimta contributes only a small, declining legacy stream, not a growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eForteo, biosimilar pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eForteo is a classic Dog in Eli Lilly and Company’s BCG Matrix: it sits in a low-growth osteoporosis market and faces heavy generic and biosimilar pressure. U.S. exclusivity ended in 2019, and teriparatide copies have kept pricing power weak, so the brand no longer supports meaningful growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, high rivalry\u003c\/li\u003e\n\u003cli\u003eGeneric pressure cuts margins\u003c\/li\u003e\n\u003cli\u003eWeak pricing power signals Dog\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCialis, generic since 2018\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCialis fits Dogs: it lost U.S. exclusivity in 2018, so Lilly no longer has the pricing power that once drove growth. By 2025, the erectile dysfunction market is mature and crowded, with low growth and many tadalafil generics, so share and margins stay weak. That makes Cialis a legacy cash tail, not a BCG growth asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGeneric since 2018\u003c\/li\u003e\n\u003cli\u003eMature, crowded ED market\u003c\/li\u003e\n\u003cli\u003eLow growth, weak share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEli Lilly’s Legacy Brands Are Losing Their Bite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn Eli Lilly and Company, Dogs are legacy brands with low growth and weak pricing power after patent loss. Cymbalta, Zyprexa, Alimta, Forteo, and Cialis now face generic-led erosion, so they add limited strategic value in 2025\/2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCymbalta\u003c\/td\u003e\n\u003ctd\u003e2013 loss, generic-led\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZyprexa\u003c\/td\u003e\n\u003ctd\u003e2011 loss, mature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlimta\u003c\/td\u003e\n\u003ctd\u003eDeclining legacy sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForteo\u003c\/td\u003e\n\u003ctd\u003e2019 loss, weak price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCialis\u003c\/td\u003e\n\u003ctd\u003e2018 loss, crowded\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKisunla, 2024 launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKisunla (donanemab) launched in July 2024 for early symptomatic Alzheimer’s disease. The market is huge: about 6.9 million Americans age 65+ live with Alzheimer’s, but Lilly is still in the early phase of uptake and share building. With high long-term potential and still modest current penetration versus Leqembi, Kisunla fits the Question Mark category.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJaypirca, 2023 launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJaypirca, launched in 2023, is Eli Lilly and Company’s newer BTK inhibitor for B-cell cancers, so it fits a Question Mark in the BCG matrix: high-growth field, still small share. BTK inhibitors remain a large market, with AbbVie and Johnson \u0026amp; Johnson still setting the pace. Eli Lilly and Company is still building Jaypirca uptake as it competes in mantle cell and chronic lymphocytic leukemia.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmvoh, 2023 launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmvoh, launched in 2023, is still in the build phase for ulcerative colitis and Crohn’s disease, two specialty markets with large, growing patient pools. Lilly is scaling against entrenched immunology brands like AbbVie and Johnson \u0026amp; Johnson, so share is still small versus the market size. That mix of low share and growth fits a Question Mark in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEbglyss, 2024 launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEbglyss, launched in 2024, gives Eli Lilly and Company a real shot in atopic dermatitis, a market that affects about 16.5 million U.S. adults and roughly 101 million people worldwide. Still, the brand is early in adoption, so its sales base is small versus mature dermatology biologics. That keeps Ebglyss in the Question Mark box.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 launch\u003c\/li\u003e\n\u003cli\u003eLarge, growing AD market\u003c\/li\u003e\n\u003cli\u003eEarly commercial penetration\u003c\/li\u003e\n\u003cli\u003eQuestion Mark status\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRetevmo, niche RET oncology asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRetevmo targets rare RET-driven cancers, including RET fusions in about 1% to 2% of NSCLC and RET-mutant medullary thyroid cancer, so its addressable pool is small. Lilly’s 2025 sales base is still limited versus its big franchises, even if the niche is growing. That puts Retevmo in Question Mark, not Star.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall biomarker pool\u003c\/li\u003e\n\u003cli\u003eGrowing but narrow market\u003c\/li\u003e\n\u003cli\u003eLimited current share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLilly’s Question Marks: Early Growth, Big Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKisunla, Jaypirca, Omvoh, Ebglyss, and Retevmo are Eli Lilly and Company Question Marks: each sits in a large or growing niche, but 2025 uptake is still early versus entrenched rivals. Lilly is still spending to build share, so these brands have upside, but not enough scale yet to be Stars.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2025 read\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKisunla\u003c\/td\u003e\n\u003ctd\u003eEarly AD launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJaypirca\u003c\/td\u003e\n\u003ctd\u003eSmall BTK share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOmvoh\u003c\/td\u003e\n\u003ctd\u003eBuild phase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191854801161,"sku":"lly-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/lly-bcg-matrix.webp?v=1783678550","url":"https:\/\/dcfanalyst.com\/products\/lly-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}